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A simple, sensitive and specific liquid chromatography–tandem mass spectrometry (LC-MS/MS) method 
was developed for the quantification of cabozantinib (CZ) in human plasma using cabozantinib-d4 (CZD4) 
as an internal standard (IS). Chromatographic separation was performed on Xbridge C18, 50 x 4.6 mm, 
5 mm column with an isocratic mobile phase composed of 10mM Ammonium formate and Methanol in 
the ratio of (20:80 v/v), at a flow-rate of 0.7 mL/min. CZ and CZD4 were detected with proton adducts at 
m/z 502.2 → 391.1 and 506.3 → 391.2 in multiple reaction monitoring (MRM) positive mode respectively. 
Liquid-Liquid extraction method was used to extract the drug and IS. The method was validated over a 
linear concentration range of 5.0-5000.0 pg/mL with correlation coefficient (r2) ≥ 0.9994. This method 
demonstrated intra and inter-day precision within 1.95 to 2.37 and 2.93 to 9.3 % and Accuracy within 
101.4 to 102.4 and 99.5 to 104.8 %. Cabozantinib was found to be stable throughout freeze-thawing 
cycles, bench top and postoperative stability studies. 
Keywords: Cabozantinib/human plasma/validation. Mass spectrometry. Pharmacokinetic/study. 
INTRODUCTION
Tyrosine kinases (TKs) are deemed potential targets 
for new drug development, especially for cancer and 
rheumatoid arthritis drugs. Over the last decade, several 
tyrosine kinase inhibitors (TKIs) have been developed 
and approved for the treatment of various types of cancer, 
with each of them targeting specific signaling pathways 
(Nguyen et al., 2015). Furthermore, more recent advances 
have also led to the discovery of the Janus kinases (JAKs) 
(Tolaney et al., 2016), which by their inhibition introduced 
new therapeutic approach for cancer and immunity 
disorders (Lacy et al., 2015).
Cabozantinib is a small molecule inhibitor of 
tyrosine kinases including the hepatocyte growth factor 
receptor (MET) and vascular endothelial growth factor 
receptor 2 (VEGFR2), which are important mediators of 
tumor cell survival, metastasis, and tumor angiogenesis 
(Drilon et al., 2013). In clinical studies, cabozantinib 
(Figure1) has demonstrated activity in multiple tumor 
types, with responses observed both in soft tissue disease 
and in bone metastases (Kwilas et al., 2014; Elisei et 
al., 2013). In 2011, the U.S. FDA approved CZ for the 
management of patients with progressive, metastatic 
medullary thyroid cancer; in 2015 it was also approved by 
the European Medicines Agency (EMA) for the same use.
Screening of  the  l i tera ture  d isc losed few 
published reports for the quantification of cabozantinib 
concentration in pharmacokinetics of cabozantinib in 
healthy adult subjects (Kwilas et al., 2014; Elisei et al., 
2013; Choueiri et al., 2014; Zhang et al., 2009; Arora, 
Scholar, 2005; Walker et al., 2006; O’Shea, Holland, 
Staudt, 2013), rat blood with UPLC–MS/MS (Wang et 
al., 2015), stability indicating LC method by LC/TOF-
FIGURE 1 - Chemical structure of cabozantinib.
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MS (Wu et al.,2014) in rat plasma by LC-MS (Su et al., 
2015), cabozantinib in dosage form and human plasma 
via micelle-enhanced spectrofluorimetry (Darwish et al., 
2015), in human plasma and urine by LC-MS/MS (Kadi 
et al., 2016).
From the literature review it was concluded that the 
developed methods shows poor sensitivity, long retention 
time, lack of deuterated internal standard by using 
HPLC-ESI-MS/MS. There are very limited methods were 
reported for estimation of cabozantinib using deuterated 
internal standard, cabozantinib-d4 (Figure 2) in biological 
samples. 
MATERIAL AND METHODS
Chemicals and reagents
Cabozantinib (CZ) (Cadila Pharmaceuticals, India), 
Cabozantinib-d4 (CZD4) (Alsachim, France), Ammonium 
formate and sodium hydroxide (Merck, Mumbai, India), 
Methanol, ethyl acetate and dichloromethane (J. T. Baker, 
USA), Ultra pure water (Milli-Q system, Millipore, 
Bedford, MA, USA), Screened human plasma (navjeevan 
blood bank, Hyderabad, A.P). The chemicals and solvents 
were used in this study analytical and HPLC grade.
Instrumentation
The  1200  Se r i e s  HPLC sys t em (Ag i l en t 
Technologies, Germany). Mass spectrometric detection 
was performed on an API 4000 triple quadrupole 
instrument (ABI-SCIEX, Toronto, Canada) using MRM. 
Data processing was performed on Analyst 1.4.1 software 
package (SCIEX).
Detection
Detection was performed by Turbo ion spray (API) 
positive mode with Unit Resolution using MRM positive 
ion mode with mass transitions of m/z (amu) 502.2→391.1 
and 506.3→391.2 for CZ and CZD4. The mass spectra of 
parent and product ions of CZ and CZD4.
Chromatographic conditions
Chromatographic separation was performed by 
Xbridge C18, 50 x 4.6 mm 5 mm analytical column 
at 40 °C. 10mM ammonium formate and methanol in 
the ratio of (20:80 v/v) was used as mobile phase at a 
flow rate of 0.7 mL/min. Deuterated internal standard 
cabozantinib-d4 was used as appropriate internal 
standard in terms of chromatography and extractability. 
Cabozantinib and cabozantinib –d4 was eluted at 0.9 ± 
0.2 min approximately with a total run time of 3 min for 
each sample.
Preparation of standards and quality control (QC) 
samples
Standard s tock solut ions  of  cabozant in ib 
(100.0 µg/mL) and cabozantinib-d4 (IS) (100.0 µg/mL) 
was prepared in methanol. The IS spiking solutions 
(10.0 ng/mL) were prepared in reconstitution solution 
(10 mM ammonium formate and methanol in the ratio 
of (20:80 v/v)) from IS stock solution. Standard stock 
solutions and IS spiking solutions stored in refrigerator 
conditions 2 - 8 °C until analysis. Standard stock solutions 
of cabozantinib (100.0 µg/mL) was added to drug-free 
screened human plasma to obtain concentration levels of 
5.0, 10.0, 200.0, 800.0, 1400.0, 2000.0, 3000.0, 4000.0 
and 5000.0 pg/mL for analytical standards and 5.0, 15.0, 
2500.0 and 3500.0 pg/mL for Quality control standards 
and stored in the freezer at -30 °C until analysis. The 
aqueous standards were prepared in reconstitution solution 
(10 mM ammonium formate and methanol in the ratio 
of (20:80 v/v) for validation exercises and stored in the 
refrigerator at 2-8 °C until analysis.
Sample preparation
Liquid-Liquid extraction method was used to 
isolate cabozantinib and cabozantinib-d4 from human 
plasma. For this, 100 µL of cabozantinib-d4 (10 ng/mL) 
and 400 µL of plasma sample (respective concentration) 
were added into labeled polypropylene tubes and 
vortexed briefly about 5 minutes. Followed by, 100 
µL of 0. 1N NaOH solution and 3 mL of extraction 
solvent (ethyl acetate: dichloromethane 80:20v/v) were 
added and vortexed about10 minutes. Then the samples 
were centrifuge at 4000 rpm for approximately 5min 
at an ambient temperature. From this, supernatant 
sample was transferred into labeled polypropylene 
tubes and evaporate to dryness at 40 °C briefly, and 
then reconstituted wih reconstitute solution(10 mM 
ammonium formate and Methanol in the ratio of (20:80 
v/v) , vortexed and transferred the sample into auto 
sampler vials for injection. 
Selectivity and sensitivity
Selectivity was performed by analyzing the human 
blank plasma samples from six different sources (donors) 
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with an additional hemolysed group and lipedimic group to 
test for interference at the retention times of analytes. The 
sensitivity was compared with LLOQ of the analyte with 
its blank plasma sample. The peak area of blank samples 
should not be more than 20% of the mean peak area of 
LOQ of cabozantinib and 5% of the mean peak area of 
cabozantinib-d4. 
Precision and accuracy 
It was determined by replicate analysis of quality 
control samples (n = 6) at LLOQ (lower limit of 
quantification), LQC (low quality control), MQC (medium 
quality control), HQC (high quality control) and ULOQ 
(upper limit of quantification) levels. The % CV should be 
less than 15%, and accuracy should be within 15% except 
LLOQ where it should be within 20%.
Matrix effect
The matrix effect due to the plasma matrix was used 
to evaluate the ion suppression/enhancement in a signal 
when comparing the absolute response of QC samples 
after pretreatment (LLE) with the reconstitution samples 
extracted blank plasma sample spiking with analyte. 
Experiments were performed at MQC levels in triplicate 
with six different plasma lots with the acceptable precision 
(%CV) of ≤ 15%.
Recovery
The extraction recovery of Analyte and IS from 
human plasma was determined by analyzing quality 
control samples. Recovery at three concentrations (15.0, 
2500.0, and 3500.0 pg/mL) was determined by comparing 
peak areas obtained from the plasma sample, and the 
standard solution spiked with the blank plasma residue. A 
recovery of more than 50 % was considered adequate to 
obtain required sensitivity.
Stability (freeze - thaw, auto sampler, bench top, 
long term)
Low quality control and high quality control samples 
(n=6) were retrieved from the deep freezer after three 
freeze-thaw cycles according to the clinical protocol. 
Samples were stored at -30 °C in three cycles of 24, 36 and 
48 h. In addition, the long-term stability of CZ in quality 
control samples was also evaluated by analysis after 
105 days of storage at -30 °C. Autosampler stability was 
studied following 53 h storage period in the autosampler 
tray with control concentrations. Room temperature 
stability was studied for 24.5 h period with control 
concentrations. Stability samples were processed and 
extracted along with the freshly spiked calibration curve 
standards. The precision and accuracy for the stability 
samples must be within ≤ 15 and ± 15% respectively of 
their nominal concentrations.
RESULTS AND DISCUSSION
Method development
During method development, different options 
were evaluated to optimize mass spectrometry detection 
parameters, chromatography and sample extraction.
Mass spectrometry detection parameters 
optimization
Electro spray ionization (ESI) provided a maximum 
response over atmospheric pressure chemical ionization 
(APCI) mode, and was chosen for this method. The 
instrument was optimized to obtain sensitivity and signal 
stability during infusion of the analyte in the continuous 
flow of mobile phase to electrospray ion source operated 
at both polarities at a flow rate of 5μL/min. Cabozantinib 
gave more response in positive ion mode as compare to 
the negative ion mode. The predominant peaks in the 
primary ESI spectra of cabozantinib and cabozantinib-d4 
corresponds to the [M+H]+ ions at m/z 502.2 and 
506.3 (Figure 3). Product ions of cabozantinib and 
cabozantinib-d4 scanned in quadrupole 3 after a collision 
with nitrogen in quadrupole 2 had an m/z of 391.1 and 
391.2 (Figure 4). Mass parameters were optimised as 
Source temperature 500 °C, Heater gas 45 (nitrogen) psi, 
nebulizer gas 30 (nitrogen) psi, Curtain gas 20 (nitrogen) 
psi, CAD gas 5 (nitrogen) psi, Ion Spray (IS) voltage 5500 
volts, Source flow rate 600 µL/min without split, Entrance 
potential 10 V, Declustering potential 70 V, Collision 
energy 30 V, Collision cell exit potential 15 V for both 
Analyte and I.S.
FIGURE 2 - Chemical structure of cabozantinib-d4.
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Chromatography optimization
Initially, a mobile phase consisting of ammonium 
acetate and acetonitrile in varying combinations was 
tried, but a low response was observed. The mobile phase 
containing 5mM ammonium formate: acetonitrile (20:80 
v/v) and 5mM ammonium formate: methanol (20:80 
v/v) gives the better response, but poor peak shape was 
observed. A mobile phase of 0.1% formic acid in water in 
combination with methanol and acetonitrile with varying 
combinations were tried. Using a mobile phase containing 
10mM ammonium formate: methanol (20:80 v/v) gave the 
best signal along with a marked improvement in the peak 
shape was observed for cabozantinib and cabozantinib-d4. 
Short length columns, such as Symmetry Shield RP18 
(50 x 2.1 mm, 3.5 μm), Inertsil ODS-2V (50 x 4.6 mm, 
5μm), Hypurity C18 (50 x 4.6 mm, 5 μm) and Hypurity 
Advance (50 x 4.0 mm, 5 μm), Xbridge C18, 50x4.6 
mm 5 μm were tried during the method development. 
Xbridge C18, 50x4.6 mm 5 μm column gave a relatively 
good peak shape with the best signal was obtained. It 
gave satisfactory peak shapes for both cabozantinib and 
cabozantinib-d4. Flow rate of 0.7 mL/min without splitter 
was utilized and reduced the run time to 2.5 min for both 
drug and IS were eluted with shorter time at 0.9±0.2 min. 
For an LC-MS/MS analysis, utilization of stable isotope-
labeled or suitable analog drugs as an internal standard 
proves helpful when a significant matrix effect is possible. 
In our case, cabozantinib-d4 was found to be best for 
the present purpose. The column oven temperature was 
kept at a constant temperature of about 40 °C. Injection 
volume of 5 µL sample is adjusted for better ionization 
and chromatography.
Extraction optimization
Prior to load the sample for LC injection, the co-
extracted proteins should be removed from the prepared 
FIGURE 3 - Parent and product ion mass spectra of cabozantinib.
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solution. For this purpose, initially we tested with different 
extraction procedures like PPT (Protein Precipitation), 
LLE (Liquid Liquid extraction), and SPE (Solid Phase 
extraction). We found ion suppression effect in protein 
precipitation method for drug and internal standard. 
Further, we tried with SPE and LLE. Out of all we 
observed LLE is suitable for extraction of drug and IS. 
We tried with several organic solvents (ethyl acetate, 
chloroform, n-hexane, dichloro methane and methyl 
tertiary butyl ether) individually as well with combinations 
in LLE to extract analyte from the plasma sample. In our 
case ethyl acetate: dichloromethane (80:20) combination 
served as good extraction solvent. Auto sampler wash is 
optimized as 80% methanol. High recovery and selectivity 
was observed in the Liquid-Liquid extraction method. 
These optimized detection parameters, chromatographic 
conditions and extraction procedure resulted in reduced 
analysis time with accurate and precise detection of 
cabozantinib in human plasma.
Method validation
A thorough and complete method validation of 
cabozantinib in human plasma was done following US 
FDA guidelines (FDA, 2001). The method was validated 
for selectivity, sensitivity, matrix effect, linearity, precision 
and accuracy, recovery and stability. 
Selectivity and specificity
The analysis of CZ and CZD4 using MRM function 
was highly selective with no interfering compounds. 
(Figure 5). Specificity was performed by using six different 
lots of human plasma. Here showing only blank plasma 
interference. Chromatograms obtained from plasma spiked 
with CZ (5.0 pg/mL) and CZD4 (10.0 ng/mL) are shown 
in (Figure 5 and 6). 
Matrix effect
The overall precision of the matrix factor is 
expressed as Coefficient of Variation (CV %) and was 
determined to be 1.23 for CZ.
Linearity
Calibration curves were plotted as the peak area 
ratio (CZ/CZD4) versus (CZ) concentration. Calibration 
was found to be linear over the concentration range of 5.0-
FIGURE 4 - Parent and product ion mass spectra of cabozantinib-d4.
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FIGURE 5 - MRM chromatogram of Blank human plasma.
FIGURE 6 - Chromatogram of cabozantinib and cabozantinib-d4 at LOQ level.
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5000.0 pg/mL. The % CV was less than 3.21%, and the 
accuracy ranged from 97.9 to 102.2 %. The determination 
coefficients (r2) were greater than 0.9994 for all curves 
(Table I).
Precision and accuracy
Precision and accuracy for this method were 
controlled by calculating the intra and inter-batch 
variations at four concentrations (5.0, 15.0, 2500.0 and 
3500.0 pg/mL) of QC samples in six replicates. As shown 
in (Table II), the intra-batch % CV was less than 2.37% 
and the accuracy ranged from 101.4 to 102.4%. Inter-
batch % CV was less than 9.3% and the accuracy ranged 
from 99.5 to 104.8%. These results indicate the adequate 
reliability and reproducibility of this method within the 
analytical range.
Recovery
The recovery following the sample preparation 
using Liquid-Liquid extraction method was calculated by 
comparing the peak area ratios of CZ in plasma samples 
with the peak area ratios of solvent samples and was 
estimated at control levels of CZ. The recovery of CZ 
was determined at three different concentrations 15.0, 
2500.0 and 3500.0 pg/mL, were found to be 89.70, 90.2 
and 91.2%, respectively. The overall average recovery 
of CZ and CZD4 was found to be 90.3 and 92.5% 
respectively.
Limit of quantification (LOQ) and limit of detection 
(LOD)
The limit of quantification was determined at 
5 pg/mL. The limit of detection was determined at 
50 pg/10 μL injection volume.
Stability (freeze-thaw, auto sampler, bench top, long 
term) 
Quantification of the CZ in plasma subjected 
to 3 freeze-thaw (-30 °C to room temperature) cycles 
showed the stability of the analyte. No significant 
degradation of the CZ was observed even after 53 h 
storage period in the autosampler tray and the % 
TABLE I - Calibration curve details from one batch of the validation section
Spiked plasma 
concentration 
(pg/mL)
Concentration 
measured(mean) 
(pg/mL)
SD (%) CV (n = 5) Accuracy %
5.0 5.1 0.1 1.9 102.0
10.0 9.8 0.3 3.2 97.9
200.0 199.6 6.4 0.2 99.8
800.0 817.9 4.2 0.51 102.2
1400.0 1403.7 21.46 1.53 99.3
2000.0 2022.56 25.8 1.27 100.3
3000.0 2993.05 25.1 0.84 100.0
4000.0 4010.11 30 0.74 99.2
5000.0 5014.1 89.38 1.78 100.5
TABLE II - Precision and accuracy (analysis with spiked plasma samples at four different concentrations)
Spiked plasma 
concentration 
(pg/mL)
Within-run Between-run
Concentration 
measured 
(n=6) (pg/mL)  
(Mean ± S.D.)
(%)CV Accuracy %
Concentration 
measured 
(n=30) (pg/mL) 
(Mean ± S.D.)
(%)CV Accuracy %
5.0 5.12±0.1 2.22 102.43 5.24±0.1 9.30 104.8
15.0 15.28±0.3 2.37 101.9 14.92±0.3 7.66 99.5
2500.0 2535±21.4 2.04 101.45 2495.2±25.1 2.93 99.8
3500.0 3577.1±25.2 1.95 102.21 3550.7±25.5 3.98 101.4
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accuracy of CZ was between 97.18 to 103.27% of the 
theoretical values. Room temperature stability at 24.5 h 
was between 98.0 to 99.4% of the theoretical values. In 
addition, the long-term stability of CZ in QC samples 
after 105 days of storage at -30 °C was also evaluated. 
The % accuracy ranged from 99.7 to 101.82% of the 
theoretical values. These results confirmed the stability 
of CZ in human plasma for at least 105 days at -30 °C 
(Table III).
CONCLUSION
The proposed method was five folds higher sensitive 
than the reported method and analyte was compared with 
deuterated internal standard. The method described here is 
fast (requires less than 2.5 min of analysis time), rugged, 
reproducible bioanalytical method. The developed method 
is simple and efficient and can be used in pharmacokinetics 
studies as well as in the monitoring of the investigated 
analyte in bodyfluids.
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